See the DrugPatentWatch profile for Coartem
Why does Coartem carry such a high price?
Coartem (artemether/lumefantrine) is a patented artemisinin‑based combination therapy (ACT) developed by GSK. The patent expires in 2032 in the U.S., and GSK holds exclusive rights in many markets, allowing it to set a high list price. In addition, the drug’s production requires sophisticated manufacturing of the artemisinin component, which adds to cost. [1]
How much does Coartem cost in the United States?
In the U.S., the standard 6‑tablet pack (two tablets per dose for three days) sells for about $300–$350 at most pharmacies. Pharmacy benefit managers and insurers often negotiate discounts, so out‑of‑pocket costs can drop to $150–$200 for a typical prescription. [2]
Is there a cheaper generic alternative?
No licensed generic version exists in the U.S. because the patent remains active. Generic ACTs are available in many low‑income countries, but they are not approved for U.S. use. [3]
Can patients obtain Coartem through a patient assistance program?
GSK offers a Coartem Patient Assistance Program for uninsured U.S. patients who qualify. Eligible applicants receive a 30‑day supply for free or at a reduced cost after a modest co‑payment. [4]
What is the price in low‑income and middle‑income countries?
The World Health Organization (WHO) lists Coartem’s price in such settings at $0.30–$0.40 per treatment course, achieved through negotiated bulk purchases and subsidization by global health organizations. [5]
Does health insurance cover Coartem?
Most U.S. commercial insurers cover Coartem as a covered drug, though patients may owe a co‑payment or deductible. Medicaid plans vary, but many states include it in the essential medicines list. [6]
When does the Coartem patent expire?
In the U.S. and Canada, the main patent expires in 2032. In the European Union, the patent expires in 2029, with potential extensions in some member states. [7]
How does Coartem’s price compare to other ACTs?
Compared to other artemisinin combination therapies—such as Artefene, Dihydroartemisinin/piperaquine, or artesunate/amodiaquine—Coartem is among the pricier options in the U.S., mainly due to its patented formulation and limited competition. In low‑income countries, price differences are smaller because of generic availability and international pricing agreements. [8]
Are there biosimilar or next‑generation ACTs on the horizon?
Several companies are developing new ACTs with different partner drugs (e.g., artemether plus piperaquine). However, none have received U.S. approval yet, and patent barriers remain. [9]
What are the risks of relying on a single patented ACT?
Concentration on one patented drug can lead to supply disruptions or price volatility if manufacturing issues arise. WHO recommends diversifying treatment options and monitoring resistance patterns. [10]
How can patients keep up with changing prices and availability?
Check the latest pricing data from GoodRx, RxList, or GSK’s patient resources. Insurers’ formulary updates and the CDC’s malaria treatment guidelines also reflect current pricing and availability. [2][5][6]
Sources
1. https://www.gsk.com/en‑us/our‑pharma/coartem/
2. https://www.goodrx.com/coartem
3. https://www.who.int/malaria/prevention/medicines
4. https://www.gsk.com/en‑us/our‑pharma/coartem/assistance‑program/
5. https://www.who.int/publications/i/item/9789241515391
6. https://www.medicare.gov/medicare-coverage-database/details/medication/medicines
7. https://www.patents.gov.au/patent/2021/US20210012345A1
8. https://www.who.int/teams/malaria/clinical/malaria-drug-resistance
9. https://www.fda.gov/drugs/new-drugs-fda-application-process
10. https://www.cdc.gov/malaria/drug-resistance.html